' Transformational' Results in Squamous Cell Lung Cancer'Transformational' Results in Squamous Cell Lung Cancer
An immuno-chemotherapy combination again moves the bar forward in a difficult-to-treat subset of squamous cell lung cancer patients.Medscape Medical News
Recently, many combination therapies involving an immune checkpoint inhibitor targeting the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway and another treatment option such as chemotherapy, radiation therapy, and various immunotherapy agents have been explored to improve the response rate and clinical outcomes in various solid tumors including non-small cell lung cancer (NSCLC) [1 –8]. Especially, combination therapy with an indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor and a PD-1/PD-L1 inhibitor is expected to be a novel and effective treatment option and is currently attracting a lot of attention.
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) Combining immunotherapy with chemotherapy in patients with metastatic squamous cell carcinoma 'significantly increases' the survival of patients.Squamous cell carcinoma represents 20 percent to 30 percent of all cases of lung cancer and has a worse prognosis than other variants. It has the least amount of progress in terms of treatment.Patients who received chemotherapy and immunotherapy extended their survival by almost 16 months on average, compared to 11.3 months for those who received chemotherapy alone.
CONCLUSIONS Platelet activation index will be a potential marker for predicting GP resistance. Besides, CA125 ≥16.9 could be used as a potential marker for predicting GP resistance and OS, which was more sensitive than CA125 ≥35 for squamous cell carcinoma. PMID: 30498189 [PubMed - in process]
This article is protected by copyright. All rights reserved.
Discussion:The case clearly demonstrates poor prognostic indicators with hypercalcemia and severe leukocytosis in the setting of end stage lung adenosquamous carcinoma. Classically, paraneoplastic hypercalcemia is associated with PTHrP production in Squamous Cell carcinoma. Overall incidence of hypercalcemia in lung cancer ranges from to 8%-12% with median survival time (MST) of 3.8 months (1,2).Paraneoplastic Leukocytosis meanwhile is most often associated with adenocarcinoma (42%) and squamous cell carcinoma (36%) with incidence ranging between 16 and 30% and MST of 1.9 months (1,2). Nonetheless, the combination of these...
Conclusion: LC in CTD-ILD patients is an important comorbidity with an incidence of 10.5% in our population. ILD limited LC treatment and LC adversely affected overall survival.
The soluble forms of PD-1 and PD-L1 (sPD-1, sPD-L1) were detected in the blood of patients (pts) with tumors. Evidence suggests that the blood levels of sPD-1/PD-L1 might facilitate the prediction of clinic/pathological characteristics, treatment response, and survival outcomes.Aim: to evaluate soluble sPD-L1 plasma concentrations in lung cancer (LC) pts, and their correlation with clinico-pathological characteristics and treatment response.Method: Plasma samples of 95 LC pts were examined for soluble PD-L1 blood concentration with DuoSet ELISA system.Results: M:F ratio 66:29 (69.5%:30.5%), median age of 64 years (range 30...
Conclusion: This real life study confirmed efficiency of concurrent chemoradiotherapy ensuring good and long-lasting response in locally advanced NSCLC. Complimented with surgery, it gives even better results prolonging progression free survival. Results are even better than studies published so far.
Background: The results of standard chemotherapy in lung cancer are not very satisfactory, so it is important to identify genetic mutations that provide targeted therapies. Recent reports have suggested influences of racial difference on the frequency of mutation in lung cancer. We aimed to determine the frequency and regional distribution of genetic mutations in lung cancer in TURKEY.Methods: REDIGMA study is a prospective multicenter study conducted in Turkey with 25 centers, including 664 patients with non-small cell lung cancer (NSCLL) who had genetic mutation analysis and agreed to participate the study. We evaluated ...
Conclusion: Association of anti-PD1 and cyclophosphamide for the treatment of lung SCC in our model can reduce tumor evolution. A hypothesis for these results is a decrease of T regulator cells in tumors.